guanfacine and Aging
guanfacine has been researched along with Aging in 15 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Guanfacine was well tolerated, and did not lead to significant changes in blood pressure or heart rate." | 1.32 | Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. ( Kem, DL; McDougle, CJ; Posey, DJ; Puntney, JI; Sasher, TM, 2004) |
| " B-HT920 was found to produce a dose-response profile qualitatively similar to, but weaker than, clonidine: low doses impaired memory and began to lower blood pressure and produce sedation, while high doses improved memory." | 1.27 | The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. ( Arnsten, AF; Cai, JX; Goldman-Rakic, PS, 1988) |
| " Its kinetics were best described by a 2-compartment model, with an elimination half-life of the beta phase of 17 hours." | 1.27 | Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients. ( Kiechel, JR, 1986) |
Research
Studies (15)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Gamo, NJ | 1 |
| Yang, Y | 1 |
| Jin, LE | 1 |
| Wang, XJ | 1 |
| Laubach, M | 1 |
| Mazer, JA | 1 |
| Lee, D | 1 |
| Arnsten, AF | 4 |
| Decamp, E | 1 |
| Clark, K | 1 |
| Schneider, JS | 1 |
| D'Esposito, M | 1 |
| Gazzaley, A | 1 |
| Chapman, SB | 1 |
| Cotman, CW | 1 |
| Fillit, HM | 1 |
| Gallagher, M | 1 |
| van Dyck, CH | 1 |
| Posey, DJ | 1 |
| Puntney, JI | 1 |
| Sasher, TM | 1 |
| Kem, DL | 1 |
| McDougle, CJ | 1 |
| Rämä, P | 1 |
| Linnankoski, I | 1 |
| Tanila, H | 1 |
| Pertovaara, A | 1 |
| Carlson, S | 1 |
| Steere, JC | 2 |
| Jentsch, DJ | 1 |
| Li, BM | 1 |
| O'Neill, J | 1 |
| Fitten, LJ | 1 |
| Siembieda, DW | 1 |
| Ortiz, F | 1 |
| Halgren, E | 1 |
| Bissonnette, JM | 1 |
| Knopp, SJ | 1 |
| Wright, DM | 1 |
| MacMillan, LB | 1 |
| Sirviö, J | 2 |
| Riekkinen, P | 3 |
| Vajanto, I | 1 |
| Koivisto, E | 1 |
| Riekkinen, PJ | 1 |
| Jäkälä, P | 1 |
| Riekkinen, M | 1 |
| Lammintausta, R | 1 |
| McEntee, WJ | 1 |
| Crook, TH | 1 |
| Jenkyn, LR | 1 |
| Petrie, W | 1 |
| Larrabee, GJ | 1 |
| Coffey, DJ | 1 |
| Cai, JX | 1 |
| Goldman-Rakic, PS | 1 |
| Kiechel, JR | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Guanfacine for PONV and Pain After Sinus Surgery[NCT02882854] | 84 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
PACU Length of Stay in Minutes
(NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | minutes (Median) |
|---|---|
| Guanfacine | 128 |
| Placebo | 110 |
Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS)
PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. (NCT02882854)
Timeframe: 24 hours post op
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 0.00 |
| Placebo | 0.00 |
Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)
Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 24 hours postop
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 3 |
| Placebo | 2 |
Total Narcotic Requirement in PACU
Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay (NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | morphine equivalents (Median) |
|---|---|
| Guanfacine | 8.75 |
| Placebo | 7.50 |
Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)
Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 15, 30, 60 minutes after arriving in PACU
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 minutes after PACU admission72482977 | 15 minutes after PACU admission72482978 | 30 minutes after PACU admission72482977 | 30 minutes after PACU admission72482978 | 60 minutes after PACU admission72482977 | 60 minutes after PACU admission72482978 | |||||||||||||
| Mild (Pain nVRS 1-5) | Moderate/Severe (Pain nVRS 6-10) | None (Pain nVRS 0) | ||||||||||||||||
| Guanfacine | 31 | |||||||||||||||||
| Placebo | 24 | |||||||||||||||||
| Guanfacine | 0 | |||||||||||||||||
| Placebo | 5 | |||||||||||||||||
| Guanfacine | 8 | |||||||||||||||||
| Placebo | 10 | |||||||||||||||||
| Guanfacine | 18 | |||||||||||||||||
| Placebo | 20 | |||||||||||||||||
| Guanfacine | 7 | |||||||||||||||||
| Placebo | 6 | |||||||||||||||||
| Guanfacine | 14 | |||||||||||||||||
| Placebo | 14 | |||||||||||||||||
| Guanfacine | 12 | |||||||||||||||||
| Placebo | 16 | |||||||||||||||||
| Guanfacine | 6 | |||||||||||||||||
| Placebo | 13 | |||||||||||||||||
| Guanfacine | 21 | |||||||||||||||||
| Placebo | 12 | |||||||||||||||||
Reviews
1 review available for guanfacine and Aging
| Article | Year |
|---|---|
Clinical trials: new opportunities.
Topics: Aging; Alzheimer Disease; Animals; Brain; Clinical Trials as Topic; Cognition Disorders; Guanfacine; | 2012 |
Trials
1 trial available for guanfacine and Aging
| Article | Year |
|---|---|
Treatment of age-associated memory impairment with guanfacine.
Topics: Adult; Aging; Double-Blind Method; Female; Guanfacine; Humans; Male; Memory Disorders; Middle Aged; | 1991 |
Other Studies
13 other studies available for guanfacine and Aging
| Article | Year |
|---|---|
Neuronal basis of age-related working memory decline.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Aging; Animals; Biomedical Enhancement; Cue | 2011 |
Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Aging; Animals; Attention; Cogni | 2011 |
Can age-associated memory decline be treated?
Topics: Aging; Animals; Cyclic AMP; Guanfacine; Haplorhini; Humans; Memory Disorders; Memory, Short-Term; Ne | 2011 |
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
Topics: Adolescent; Adrenergic alpha-Agonists; Aging; Asperger Syndrome; Attention Deficit Disorder with Hyp | 2004 |
Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aging; Animals; Drug Interactions; Female; | 1996 |
Noradrenergic influences on prefrontal cortical cognitive function: opposing actions at postjunctional alpha 1 versus alpha 2-adrenergic receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aging; Animals; Azepines; Brimonidine Tartr | 1998 |
The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys.
Topics: Adrenergic alpha-Agonists; Aging; Animals; Attention; Brain Mapping; Discrimination Learning; Dose-R | 1997 |
Effects of guanfacine on three forms of distraction in the aging macaque.
Topics: Adrenergic alpha-Agonists; Aging; Animals; Attention; Dose-Response Relationship, Drug; Female; Guan | 2000 |
Respiratory pattern and hypoxic ventilatory response in mice functionally lacking alpha2A-adrenergic receptors.
Topics: Adrenergic alpha-Agonists; Aging; Animals; Female; Guanfacine; Hypoxia; Mice; Mice, Inbred C57BL; Mi | 2001 |
The effects of guanfacine, alpha-2 agonist, on the performance of young and aged rats in spatial navigation task.
Topics: Aging; Animals; Brain; Discrimination Learning; Dose-Response Relationship, Drug; Escape Reaction; F | 1991 |
Effects of alpha 2-drugs and pilocarpine on the high-voltage spindle activity of young and aged control and DSP4-lesioned rats.
Topics: Adrenergic alpha-Antagonists; Aging; Animals; Benzylamines; Brain Mapping; Electroencephalography; E | 1991 |
The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.
Topics: Adrenergic alpha-Agonists; Aging; Animals; Azepines; Dioxanes; Dose-Response Relationship, Drug; Fem | 1988 |
Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients.
Topics: Absorption; Acute Kidney Injury; Administration, Oral; Adult; Aged; Aging; Biological Availability; | 1986 |